Cite

HARVARD Citation

    Vansteenkiste, J. et al. (2015). Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of thoracic oncology. 10 (9), p. . [Online]. 
  
Back to record